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Abstract: Simultaneous knee arthroplasty is associated with significant blood loss. To prevent transfusion, three 
preoperative doses of epoetin- were offered to mildly anemic simultaneous knee arthroplasty patients. A retrospective 
review, using ICD-9 codes, identified twenty patients from 2007-2009. Epoetin- increased hemoglobin levels 
preoperatively (12.6 to 13.9, p<0.01). Twenty patients who did not receive epoetin- were matched to study patients. 
Study patients were transfused less (55% vs 95%, p=0.012) and had similar inpatient length of stay. The average blood 
loss without transfusion was 4.6g/dL. The mildly anemic patient is at high-risk for packed red cell transfusion during 
simultaneous knee arthroplasty. Three preoperative doses of epoetin- in the mildly anemic patient decreased total 
transfusions; however, it did not affect inpatient length of stay. 
Keywords: Single stage bilateral total knee arthroplasty, simultaneous total knee arthroplasty, epoetin-, tranexamic acid, 
degenerative joint disease, pain, anemia. 
INTRODUCTION 
 Substantial blood loss occurs during elective knee 
arthroplasty [1, 2]. Simultaneous bilateral total knee 
replacement has an even higher blood loss and, 
consequently, these patients are more likely to receive 
packed red cells [3]. However, blood transfusion is 
associated with morbidity. Furthermore, patients may refuse 
transfusion due to religious beliefs [4]. Therefore 
preoperative interventions are important to prevent 
transfusion [5-8]. 
 Approximately twelve percent of patients (65yoa) are 
mildly anemic [9]. The mildly anemic patient has a four-fold 
and fifteen-fold transfusion rate increase over patients with 
preoperative counts of 13.0-15.0g/dl and >15g/dl, 
respectively [10, 11]. Epoetin- delivered as three 
preoperative doses is believed to increase preoperative 
hemoglobin counts, and has been shown to reduce 
transfusion and decrease inpatient length of stay in the 
mildly anemic patient undergoing a revision hip and/or knee 
arthroplasty [12, 13]. Furthermore, it is unknown whether 
preoperative epoetin- is a useful intervention in the mildly 
anemic simultaneous total knee arthroplasty patient. 
 Tranexamic acid is another viable option to prevent 
allogeneic transfusion [14]. It is a synthetic serine protease 
analog that reversibly inhibits fibrinolysis – a major cause of  
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postoperative bleeding. It blocks lysine residues that bind 
plasmin and plasminogen activator molecules. The drug has 
similar applications in cardiac, urologic, and gynecologic 
surgeries as well as liver transplantation. Aprotinin and 
Aminocaproic acid have also been suggested. Aprotinin 
(derived from bovine lung) inhibits the serine protease 
during the final stage of fibrinolysis; however, allergies, 
thrombosis, nephrotoxicity, and spongiform encephalopathy 
have led to its decreased international use [15]. Furthermore, 
Aminocaproic acid is less effective, more expensive, and less 
efficacious than tranexamic acid [16]. 
 This is the first study, to the knowledge of these authors, 
to assess pre-operative epoetin- injections on the mildly 
anemic patient (10-13g/dL) undergoing simultaneous total 
knee arthroplasty. The purpose is to evaluate the preope-
rative change in hemoglobin, quantify overall blood loss, and 
to compare the percent of patients transfused with blood. The 
hypotheses are that three preoperative doses of epoetin- will 
decrease transfusions and reduce inpatient length of stay. 
METHODS 
 Following Institutional Review Board (IRB) approval, 
we performed this retrospective study. Between April 2007 
and August 2009, a retrospective review using ICD-9 
coding, identified 95 patients who underwent a simultaneous 
bilateral total knee arthroplasty. Fifty patients were mildly 
anemic (10-13g/dL), preoperatively. Twenty of these mildly 
anemic patients received three preoperative doses of epoetin-
 (21, 14, and 7 days prior to surgery). Patient-matching 
occurred by procedure, gender, BMI, ASA score, and age. 
Patient’s with pre-operative Hgb values less than 10 g/dL or 
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greater than 13g/dL, dual stage bilateral knee arthroplasty, a 
history of prior deep venous thrombosis or a pulmonary 
embolus, patients who received a postoperative drain, and 
patients with hematological diseases, cancer, or coagulation 
disorders were excluded. Mild anemia was defined by a Hgb 
level at or below 13g/dL and at or above 10g/dL [10, 11]. 
 Prior to epoetin- administration, all mildly anemic 
patients were appropriately counseled by an expert about the 
risks and benefits of preoperative anemia treatment. Anemic 
patients were considered for three weekly subcutaneous 
doses of 40,000 U of epoetin-. All injections were com-
bined with supplemental oral iron. All patients were offered 
oral multi-vitamins, vitamin B12, folic acid, and iron. 
 The preoperative work-up, surgical technique, anesthesia, 
and postoperative management of patients in both groups 
were similar. All surgeries were completed under combined 
spinal-epidural anesthesia, with tourniquet control. A straight 
medial para-patellar approach was used. All knee arthro-
plasties were cemented. Neither cell saver nor drains were 
used. Through 4-weeks postoperative, proper anticoagulation 
(either oral warfarin or subcutaneous enoxaparin) was 
administered. The target INR was 2.0-2.5. The clinical 
triggers for blood transfusion during or after the procedure 
were determined based on peri- and postoperative hemo-
globin levels, the ASA score (American Society of Ane-
sthesiologists) of the patient, and/or clinical symptoms 
consistent with an anemia. 
 Twenty patients (50%) received epoetin-. There were no 
differences between groups based on mean age (66 vs 64 
years), BMI (30.7 vs 30.8 kg/m
2
), preoperative INR (0.97 vs 
1.01), or platelet count (268,737 vs 265,750 per mm
3
) 
(p>0.05). The distribution of patients according to ASA 
score was similar (p=0.65) (Table 1). 
Table 1. Patient Demographics 
 
Characteristic Epoetin- Control P-Value 
Age 66 64 P=0.80 
BMI 30.7 30.8 P=0.90 
Preoperative INR 0.97 1.01 P=0.90 
Platelet count 268,737 265,750 P=0.70 
ASA score 2.32 2.2 P=0.65 
 
 An a priori sample size was calculated for a student’s t-
test evaluation. The anticipated effect size was 0.85, desired 
statistical power level was 0.8, and probability level was 
0.05. Therefore, the minimum sample size per group to test 
the hypothesis was 18. A chi-square test for the proportions 
of cases receiving blood, and Student’s t-test and Chi-square 
were used for comparing the continuous and categorical 
variables, respectively. For the statistical analysis, version 18 
of PASW
®
 Statistics (SPSS Inc., an IBM Company Head-
quarters, Chicago, Illinois) was used. A p<0.05 was consi-
dered statistically significant. 
RESULTS 
 The mean Hgb level at time of surgery was higher in 
patients who received preoperative epoetin- (13.9 vs 12.44 
g/dL) (p=0.0001). Epoetin- increased the preoperative 
hemoglobin level from 12.6 to 13.9 (P=0.0001). The average 
duration of surgery was similar (103 vs 109 minutes) 
(p=0.18). The intervention cohort had a blood loss from pre- 
to immediately postop of 4.6g/dL. There was no difference 
in the hemoglobin level at time of transfusion (8.2 vs 8.5) 
(p=0.31). At discharge, there was no difference in Hgb level 
(8.95 vs 8.90 g/dL) (p=0.83). Patients receiving epoetin- 
were transfused less (55% (11 of 20) vs 95% (18 of 20)) 
(p=0.012). There were no difference in number of units 
transfused (1.45 vs 1.3units) (P=0.60)). Thirty-six percent of 
transfusions occurred on postoperative day 1; thirty-six 
percent on postoperative day 2; twenty-seven percent 
occurred on postoperative day 3. There was no difference in 
day of transfusion. There was no difference in length of 
hospital stay (3.26 vs 3.25days) (p=0.95) (Table 2). 
Table 2. Results. Note that Epoetin- Increased hgb Counts 
Preoperatively and Decreased Transfusions 
 
Characteristic Epoetin- Control P-Value 
Hb at initial visit (g/dL) 12.6 to 13.9 NA P=0.0001 
Hb on day of surgery (g/dL) 13.9 12.44 P=0.0001 
Hb at time of transfusion (g/dL) 8.2 8.46 P=0.31 
Transfusion (%) 55% 95% P=0.012 
Length of Stay (days) 3.25 3.26 P=0.83 
Hb on discharge (g/dL) 8.95 8.9 P=0.83 
Duration of surgery (mins) 103 109 P=0.18 
 
 One of the patients in the control group developed 
cellulitis four days after surgery which was completely 
resolved with antibiotic treatment. Another patient in this 
group developed a myocardial infarction five days following 
knee replacement. One patient in the epoetin- group (65 
year old male) passed away seven months after surgery due 
to cardiac arrest. No other minor or major complication, 
either local or systemic, was recorded in either cohort. 
DISCUSSION 
 The blood loss during a simultaneous bilateral total knee 
arthroplasty surgery is substantial, and most mildly anemic 
(Hgb 10-13) patients will require transfusion. Three 
preoperative subcutaneous injections of 40,000 U of epoetin-
 were successful at increasing preoperative blood counts, 
and decreasing transfusion. 
 De Andrade et al. compared epoetin- to a placebo in a 
primary total knee arthroplasty double-blind study and noted 
that patients with mild anemia (10-13g/dl) who received 
epoetin- were transfused less [17]. Stowell CP et al. found 
that weekly epoetin- doses of 40,000 units raised 
hemoglobin levels from 12.3 g/dL to 13.8 g/dL, 
preoperatively. Their patients maintained higher levels peri- 
and postop compared to those receiving autologous blood 
[18]. Epoetin- increased hemoglobin levels in this study 
(12.6 to 13.9g/dl) resulting in a 40% decrease in the overall 
effect on transfusion practice. However, there was no effect 
on decreasing inpatient length of stay as demonstrated 
previously [12, 13]. 
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 All cases were performed under tourniquet control, 
which along with postoperative fibrinolysis can increase 
blood loss after arthroplasty [19-21]. Epoetin- is believed to 
transiently increase as well as improve platelet function, 
which theoretically decreases total blood loss [22]. This 
study did not calculate a hidden blood loss, but it did note 
that total blood losses during simultaneous knee arthroplasty 
were higher than primary knee, revision knee, and/or 
revision hip surgeries [23]. The change in hemoglobin from 
pre- to postop in our intervention cohort was 4.6 g/dL 
without re-infusion; such a change appears comparatively 
higher than that recorded by Sehat KR et al. who noted that a 
primary knee arthroplasty without re-infusion had a change 
of 3.3 g/dL and 2.8 g/dL after re-infusion. Interestingly, the 
change in blood count may be hidden in soft tissue and the 
joint of an arthroplasty patient [23] – which was 
demonstrated in two radio-labeled RBC studies that showed 
peri-operative blood loss into the soft tissue compartments 
[24, 25]. Although this study suggests that mildly anemic 
patients benefit from three preoperative doses of epoetin-, 
the substantial blood loss during this procedure suggests that 
the goal of ‘bloodless medicine’ may require an additional 
intervention. 
 To achieve ‘bloodless medicine’, augmenting epoetin- 
use in this population with tranexamic acid may be an 
additional option. Tranexamic has been shown to prevent 
fibrinolysis, and Ortega-Andreu M et al. showed that two 
doses, given intraoperatively, demonstrated a decrease in 
postoperative blood loss and transfusion practice in a 
multimodal protocol during primary total knee arthroplasty 
[14]. Future study to evaluate the combination of these two 
treatment modalities may demonstrate decreased blood loss 
and transfusion allowing earlier participation in physical 
therapy and/or achieving milestones sooner [2, 17, 26-28] in 
the mildly anemic simultaneous total knee arthroplasty 
population. 
 Epoetin- has been shown, in selected patient groups, to 
decrease total cost during primary knee arthroplasty [29, 30]. 
One study showed it increased direct cost per patient when 
compared to a re-transfusion system [31]; however, the 
indirect costs were not analyzed and the authors noted that 
true cost-effectiveness could not be determined. Our 
experience using epoetin- has been safe and effective at 
increasing cell counts. Furthermore, the weekly dosing 
regimen appears more patient friendly and cost effective to 
reported alternatives [32]. Furthermore, the elevated 
preoperative hemoglobin level may improve short-term 
outcomes [26]. 
 Epoetin- is thought to also have anti-apoptotic activity 
that can protect cells from hypoxic and ischemic events [33-
35]. Interestingly, cancer and chronic renal failure patients 
were noted to have an increased thrombosis rate and death 
[36-38]. This study had one unrelated cardiovascular 
incident. A myocardial event occurred seven months 
postoperative unrelated to drug use. Furthermore, all patients 
received the same immediate postoperative treatment course 
that consisted of anti-thromboprophylaxis, early ambulation, 
and physical therapy. 
 No retrospective study design is without limitation. To 
increase similarity between patient groups, patient-matching 
occurred based on age, gender, procedure, BMI, and 
American Society of Anesthesiology (ASA) scores. Each 
cohort was a consecutive series of mildly anemic (10-13 
g/dl) patients. Ninety percent of patients underwent spinal 
anesthesia in both cohorts, which is associated with 
decreased blood loss in the hypotensive patient [39]. The 
study group reported increased pre-operative iron, folic acid, 
vitamin B12, and multivitamin use. Cases were performed 
by two senior surgeons who use identical indications for 
transfusion based on peri- and postoperative hemoglobin 
levels, ASA score (American Society of Anesthesiologists), 
and/or symptomatic anemia. Lastly, no difference in ASA 
scores or hemoglobin counts at the time of transfusion 
between cohorts were noted. 
 In conclusion, the mildly anemic patient is at high-risk 
for transfusion during simultaneous bilateral total knee 
arthroplasty. A three week dosing regimen of 40,000 U of 
epoetin- increases the preoperative blood count and 
decreases transfusion. To achieve the goal of preventing 
transfusion in the mildly anemic simultaneous total knee 
arthroplasty patient, additional interventions are likely 
necessary to not only achieve ‘bloodless medicine’, but also 
increase participation in physical therapy, achieve milestones 
sooner, and decrease overall inpatient length of stay. 
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